What are you looking for?

Need help finding what you are looking for? Contact Us

Compare

Free Samples

Home Market Research Reports Pharmaceutical

Genome-based Drug Discovery Biomarker

PUBLISHER: 360iResearch | PRODUCT CODE: 1615420

PUBLISHER: 360iResearch | PRODUCT CODE: 1615420

Genomic Biomarker Market by Product (Consumables, Services, Software), Type (Predictive Biomarkers, Prognostic Biomarkers), Disease Indication, End-User - Global Forecast 2025-2030

PUBLISHED: December 1, 2024

PAGES: 191 Pages

DELIVERY TIME: 1-2 business days

ADD TO COMPARE

SELECT AN OPTION

List of Tables

The Genomic Biomarker Market was valued at USD 4.40 billion in 2023, expected to reach USD 4.67 billion in 2024, and is projected to grow at a CAGR of 6.67%, to USD 6.92 billion by 2030.

Genomic biomarkers are DNA/RNA signatures used to measure and evaluate biological processes or responses, pivotal in driving precision medicine advances by enabling individualized therapeutic approaches. The need for genomic biomarkers is driven by the increasing prevalence of chronic diseases, a surge in precision medicine research, and the shifts towards personalized healthcare solutions. These biomarkers find significant applications in personalized medicine, disease diagnosis, drug discovery and development, and risk assessment. Their end-use spans across oncology, cardio-metabolic disorders, neurology, and infectious diseases, providing tailored health solutions to improve patient outcomes and reduce healthcare costs. Market growth is influenced by technological advancements like next-gen sequencing, rising demand for personalized medicine, and increased investments by pharmaceutical and biotech companies. Governments are also fostering R&D through strategic funding and supportive regulatory frameworks. However, challenges such as high costs of genomic technologies, ethical concerns related to genetic data privacy, and the complexity of biomarker validation may hinder market growth. The constant evolution of genomics necessitates robust computational tools and methodologies to analyze complex datasets, representing a significant innovation area. Precision oncology can benefit greatly, where genomic biomarkers guide optimal cancer therapies. Opportunities lie in developing cost-effective solutions and point-of-care testing innovations, encouraging collaborations between biotech firms and academic institutions to expedite clinical implementations. The competitive landscape shows an increasing trend of mergers and strategic alliances to broaden technology portfolios and market reach. Focusing on technology integration and addressing data privacy concerns can forge a successful path forward. The nature of the genomic biomarker market is dynamic and rapidly evolving, driven by innovation, regulatory changes, and the progressing knowledge base in genomics, providing a potent platform for investments aiming at long-term sustainability and competitive advantage in the biopharmaceutical industry.

KEY MARKET STATISTICS
Base Year [2023]	USD 4.40 billion
Estimated Year [2024]	USD 4.67 billion
Forecast Year [2030]	USD 6.92 billion
CAGR (%)	6.67%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Genomic Biomarker Market

The Genomic Biomarker Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

Market Drivers
- Increasing usage of genomic biomarkers in early detection and diagnosis of chronic disease
- Governments and regulatory support for genomic biomarker research
- Growing applications of genomic biomarkers in personalized medicine
Market Restraints
- High cost and technical issues associated with developing genomic biomarkers
Market Opportunities
- Integration of AI and machine learning with genomic studies
- Growing interest in developing advanced noninvasive genomic biomarkers
Market Challenges
- Ethical and legal concerns regarding the use of genomic biomarkers

Porter's Five Forces: A Strategic Tool for Navigating the Genomic Biomarker Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Genomic Biomarker Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Genomic Biomarker Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Genomic Biomarker Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Genomic Biomarker Market

A detailed market share analysis in the Genomic Biomarker Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Genomic Biomarker Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Genomic Biomarker Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Genomic Biomarker Market

A strategic analysis of the Genomic Biomarker Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Genomic Biomarker Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agilent Technologies, Inc., APIS Assay Technologies Limited, Augurex Life Sciences Corp, Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Biocrates Life Sciences AG, Biostarks Laboratories SA, Bruker Corporation, CD Genomics, Charles River Laboratories, Inc., DH Life Sciences, LLC., Elo Health, Inc., Eurofins Scientific corporation, F. Hoffmann-La Roche Ltd, Illumina Inc., Merck KGaA, Myriad Genetics, Inc, Owkin, Inc, and Thermo Fisher Scientific company.

Market Segmentation & Coverage

This research report categorizes the Genomic Biomarker Market to forecast the revenues and analyze trends in each of the following sub-markets:

Based on Product, market is studied across Consumables, Services, and Software.
Based on Type, market is studied across Predictive Biomarkers and Prognostic Biomarkers.
Based on Disease Indication, market is studied across Cardiovascular Diseases, Neurological Diseases, Oncology, and Renal Disorders.
Based on End-User, market is studied across Diagnostic Centers, Hospitals, and Research Institutions.
Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Product Code: MRR-CB04E0565332

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Increasing usage of genomic biomarkers in early detection and diagnosis of chronic disease
  - 5.1.1.2. Governments and regulatory support for genomic biomarker research
  - 5.1.1.3. Growing applications of genomic biomarkers in personalized medicine
- 5.1.2. Restraints
  - 5.1.2.1. High cost and technical issues associated with developing genomic biomarkers
- 5.1.3. Opportunities
  - 5.1.3.1. Integration of AI and machine learning with genomic studies
  - 5.1.3.2. Growing interest in developing advanced noninvasive genomic biomarkers
- 5.1.4. Challenges
  - 5.1.4.1. Ethical and legal concerns regarding the use of genomic biomarkers
5.2. Market Segmentation Analysis
- 5.2.1. Type: Proliferating use of prognostic biomarkers in pharmaceutical research
- 5.2.2. End-user: Expanding application of genomic biomarkers in diagnostic centers
5.3. Porter's Five Forces Analysis
- 5.3.1. Threat of New Entrants
- 5.3.2. Threat of Substitutes
- 5.3.3. Bargaining Power of Customers
- 5.3.4. Bargaining Power of Suppliers
- 5.3.5. Industry Rivalry
5.4. PESTLE Analysis
- 5.4.1. Political
- 5.4.2. Economic
- 5.4.3. Social
- 5.4.4. Technological
- 5.4.5. Legal
- 5.4.6. Environmental

6. Genomic Biomarker Market, by Product

6.1. Introduction
6.2. Consumables
6.3. Services
6.4. Software

7. Genomic Biomarker Market, by Type

7.1. Introduction
7.2. Predictive Biomarkers
7.3. Prognostic Biomarkers

8. Genomic Biomarker Market, by Disease Indication

8.1. Introduction
8.2. Cardiovascular Diseases
8.3. Neurological Diseases
8.4. Oncology
8.5. Renal Disorders

9. Genomic Biomarker Market, by End-User

9.1. Introduction
9.2. Diagnostic Centers
9.3. Hospitals
9.4. Research Institutions

10. Americas Genomic Biomarker Market

10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Genomic Biomarker Market

11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa Genomic Biomarker Market

12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape

13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
- 13.3.1. Bio-Rad Introduces Revolutionary Multiplexed Digital PCR Assay for Enhanced Breast Cancer Research
- 13.3.2. Biofidelity's Introduction ASPYRE-Lung RUO Reagents for Enhanced and Rapid Genomic Biomarker Analysis
- 13.3.3. Illumina's Breakthrough in Oncology TruSight Oncology 500 ctDNA v2 Enhances Solid Tumor Genomic Profiling
13.4. Strategy Analysis & Recommendation

Companies Mentioned

1. Abbott Laboratories
2. Agilent Technologies, Inc.
3. APIS Assay Technologies Limited
4. Augurex Life Sciences Corp
5. Bio-Rad Laboratories, Inc.
6. Bio-Techne Corporation
7. Biocrates Life Sciences AG
8. Biostarks Laboratories SA
9. Bruker Corporation
10. CD Genomics
11. Charles River Laboratories, Inc.
12. DH Life Sciences, LLC.
13. Elo Health, Inc.
14. Eurofins Scientific corporation
15. F. Hoffmann-La Roche Ltd
16. Illumina Inc.
17. Merck KGaA
18. Myriad Genetics, Inc
19. Owkin, Inc
20. Thermo Fisher Scientific company

Product Code: MRR-CB04E0565332

LIST OF FIGURES

FIGURE 1. GENOMIC BIOMARKER MARKET RESEARCH PROCESS
FIGURE 2. GENOMIC BIOMARKER MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL GENOMIC BIOMARKER MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
FIGURE 7. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
FIGURE 9. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2023 VS 2030 (%)
FIGURE 11. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 13. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. AMERICAS GENOMIC BIOMARKER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 15. AMERICAS GENOMIC BIOMARKER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. UNITED STATES GENOMIC BIOMARKER MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 17. UNITED STATES GENOMIC BIOMARKER MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. ASIA-PACIFIC GENOMIC BIOMARKER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. ASIA-PACIFIC GENOMIC BIOMARKER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA GENOMIC BIOMARKER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA GENOMIC BIOMARKER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. GENOMIC BIOMARKER MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 23. GENOMIC BIOMARKER MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

TABLE 1. GENOMIC BIOMARKER MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL GENOMIC BIOMARKER MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GENOMIC BIOMARKER MARKET DYNAMICS
TABLE 7. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY SERVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY PREDICTIVE BIOMARKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY PROGNOSTIC BIOMARKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY NEUROLOGICAL DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY RENAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. AMERICAS GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 24. AMERICAS GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 25. AMERICAS GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 26. AMERICAS GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 27. AMERICAS GENOMIC BIOMARKER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 28. ARGENTINA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 29. ARGENTINA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 30. ARGENTINA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 31. ARGENTINA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 32. BRAZIL GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 33. BRAZIL GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 34. BRAZIL GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 35. BRAZIL GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 36. CANADA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 37. CANADA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 38. CANADA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 39. CANADA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 40. MEXICO GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 41. MEXICO GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 42. MEXICO GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 43. MEXICO GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 44. UNITED STATES GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 45. UNITED STATES GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES GENOMIC BIOMARKER MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 49. ASIA-PACIFIC GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 50. ASIA-PACIFIC GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 51. ASIA-PACIFIC GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 52. ASIA-PACIFIC GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 53. ASIA-PACIFIC GENOMIC BIOMARKER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 54. AUSTRALIA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 55. AUSTRALIA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 56. AUSTRALIA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 57. AUSTRALIA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 58. CHINA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 59. CHINA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 60. CHINA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 61. CHINA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 62. INDIA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 63. INDIA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 64. INDIA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 65. INDIA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 66. INDONESIA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 67. INDONESIA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 68. INDONESIA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 69. INDONESIA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 70. JAPAN GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 71. JAPAN GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 72. JAPAN GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 73. JAPAN GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 74. MALAYSIA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 75. MALAYSIA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 76. MALAYSIA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 77. MALAYSIA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 78. PHILIPPINES GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 79. PHILIPPINES GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 80. PHILIPPINES GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 81. PHILIPPINES GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 82. SINGAPORE GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 83. SINGAPORE GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 84. SINGAPORE GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 85. SINGAPORE GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 86. SOUTH KOREA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 87. SOUTH KOREA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 88. SOUTH KOREA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 89. SOUTH KOREA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 90. TAIWAN GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 91. TAIWAN GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 92. TAIWAN GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 93. TAIWAN GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 94. THAILAND GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 95. THAILAND GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 96. THAILAND GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 97. THAILAND GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 98. VIETNAM GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 99. VIETNAM GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 100. VIETNAM GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 101. VIETNAM GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA GENOMIC BIOMARKER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 107. DENMARK GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 108. DENMARK GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 109. DENMARK GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 110. DENMARK GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 111. EGYPT GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 112. EGYPT GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 113. EGYPT GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 114. EGYPT GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 115. FINLAND GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 116. FINLAND GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 117. FINLAND GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 118. FINLAND GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 119. FRANCE GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 120. FRANCE GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 121. FRANCE GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 122. FRANCE GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 123. GERMANY GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 124. GERMANY GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 125. GERMANY GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 126. GERMANY GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 127. ISRAEL GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 128. ISRAEL GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 129. ISRAEL GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 130. ISRAEL GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 131. ITALY GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 132. ITALY GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 133. ITALY GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 134. ITALY GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 135. NETHERLANDS GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 136. NETHERLANDS GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 137. NETHERLANDS GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 138. NETHERLANDS GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 139. NIGERIA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 140. NIGERIA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 141. NIGERIA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 142. NIGERIA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 143. NORWAY GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 144. NORWAY GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 145. NORWAY GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 146. NORWAY GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 147. POLAND GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 148. POLAND GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 149. POLAND GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 150. POLAND GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 151. QATAR GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 152. QATAR GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 153. QATAR GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 154. QATAR GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 155. RUSSIA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 156. RUSSIA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 157. RUSSIA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 158. RUSSIA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 159. SAUDI ARABIA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 160. SAUDI ARABIA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 161. SAUDI ARABIA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 162. SAUDI ARABIA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 163. SOUTH AFRICA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 164. SOUTH AFRICA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 165. SOUTH AFRICA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 166. SOUTH AFRICA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 167. SPAIN GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 168. SPAIN GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 169. SPAIN GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 170. SPAIN GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 171. SWEDEN GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 172. SWEDEN GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 173. SWEDEN GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 174. SWEDEN GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 175. SWITZERLAND GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 176. SWITZERLAND GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 177. SWITZERLAND GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 178. SWITZERLAND GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 179. TURKEY GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 180. TURKEY GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 181. TURKEY GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 182. TURKEY GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 183. UNITED ARAB EMIRATES GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 184. UNITED ARAB EMIRATES GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 185. UNITED ARAB EMIRATES GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 186. UNITED ARAB EMIRATES GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 187. UNITED KINGDOM GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 188. UNITED KINGDOM GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 189. UNITED KINGDOM GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 190. UNITED KINGDOM GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 191. GENOMIC BIOMARKER MARKET SHARE, BY KEY PLAYER, 2023
TABLE 192. GENOMIC BIOMARKER MARKET, FPNV POSITIONING MATRIX, 2023